Alvotech In-Licenses Xolair Rival From BiosanaPharma

Co-Development Deal Will See Pair Collaborate On Omalizumab Biosimilar

 
• By David Wallace
  
Licensing Neon Sign Wall
The licensing deal targets a $3.3bn opportunity in Xolair • Source: kaarle dev / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business